Mustgrow Biologics Corp Stock Debt To Equity
| MGRO Stock | 1.10 0.05 4.76% |
MustGrow Biologics Corp fundamentals help investors to digest information that contributes to MustGrow Biologics' financial success or failures. It also enables traders to predict the movement of MustGrow Stock. The fundamental analysis module provides a way to measure MustGrow Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MustGrow Biologics stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.14 | 0.13 |
MustGrow | Debt To Equity |
MustGrow Biologics Corp Company Debt To Equity Analysis
MustGrow Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current MustGrow Biologics Debt To Equity | 0.13 |
Most of MustGrow Biologics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MustGrow Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MustGrow Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for MustGrow Biologics is extremely important. It helps to project a fair market value of MustGrow Stock properly, considering its historical fundamentals such as Debt To Equity. Since MustGrow Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MustGrow Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MustGrow Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
MustGrow Total Stockholder Equity
Total Stockholder Equity |
|
MustGrow Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MustGrow Biologics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MustGrow Biologics could also be used in its relative valuation, which is a method of valuing MustGrow Biologics by comparing valuation metrics of similar companies.MustGrow Biologics is currently under evaluation in debt to equity category among its peers.
MustGrow Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | 0.012 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 50.07 M | ||||
| Shares Outstanding | 51.64 M | ||||
| Shares Owned By Insiders | 10.78 % | ||||
| Number Of Shares Shorted | 12.86 K | ||||
| Price To Book | 14.47 X | ||||
| Price To Sales | 11.51 X | ||||
| Revenue | 4.71 M | ||||
| Gross Profit | (190.72 K) | ||||
| Net Income | (676.94 K) | ||||
| Total Debt | 618.41 K | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (294.76 K) | ||||
| Short Ratio | 0.33 X | ||||
| Beta | 1.66 | ||||
| Market Capitalization | 54.22 M | ||||
| Total Asset | 6.94 M | ||||
| Retained Earnings | (23.28 M) | ||||
| Working Capital | 5.73 M | ||||
| Net Asset | 6.94 M |
About MustGrow Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MustGrow Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MustGrow Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MustGrow Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MustGrow Stock Analysis
When running MustGrow Biologics' price analysis, check to measure MustGrow Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MustGrow Biologics is operating at the current time. Most of MustGrow Biologics' value examination focuses on studying past and present price action to predict the probability of MustGrow Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MustGrow Biologics' price. Additionally, you may evaluate how the addition of MustGrow Biologics to your portfolios can decrease your overall portfolio volatility.